JP2007504271A - Crf1受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類 - Google Patents

Crf1受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類 Download PDF

Info

Publication number
JP2007504271A
JP2007504271A JP2006526210A JP2006526210A JP2007504271A JP 2007504271 A JP2007504271 A JP 2007504271A JP 2006526210 A JP2006526210 A JP 2006526210A JP 2006526210 A JP2006526210 A JP 2006526210A JP 2007504271 A JP2007504271 A JP 2007504271A
Authority
JP
Japan
Prior art keywords
pyridin
pyrrolo
alkyl
methoxy
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006526210A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504271A5 (https=
Inventor
ゲー ピン
エフ ホルヴァート レイモンド
ル ジャン イエン
泰史 山口
カイザー バーンド
ジャン シュエチョン
ジャン ソミン
ジャオ ヒ
ジョン スタンリー
ムーアクロフト ニール
シャッツケ グレッグ
Original Assignee
ニューロジェン・コーポレーション
アヴェンティス ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34272952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2007504271(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ニューロジェン・コーポレーション, アヴェンティス ファーマシューティカルズ インコーポレイテッド filed Critical ニューロジェン・コーポレーション
Publication of JP2007504271A publication Critical patent/JP2007504271A/ja
Publication of JP2007504271A5 publication Critical patent/JP2007504271A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2006526210A 2003-09-05 2004-09-03 Crf1受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類 Pending JP2007504271A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50041403P 2003-09-05 2003-09-05
PCT/US2004/028899 WO2005023806A2 (en) 2003-09-05 2004-09-03 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands

Publications (2)

Publication Number Publication Date
JP2007504271A true JP2007504271A (ja) 2007-03-01
JP2007504271A5 JP2007504271A5 (https=) 2007-11-29

Family

ID=34272952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006526210A Pending JP2007504271A (ja) 2003-09-05 2004-09-03 Crf1受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類

Country Status (19)

Country Link
US (2) US20050113379A1 (https=)
EP (1) EP1680424A2 (https=)
JP (1) JP2007504271A (https=)
KR (1) KR20060088534A (https=)
CN (1) CN1878773A (https=)
AP (1) AP2006003559A0 (https=)
AR (1) AR045582A1 (https=)
AU (1) AU2004270713A1 (https=)
BR (1) BRPI0414087A (https=)
CA (1) CA2537829A1 (https=)
CR (1) CR8274A (https=)
EA (1) EA200600372A1 (https=)
EC (1) ECSP066408A (https=)
IL (1) IL174084A0 (https=)
MA (1) MA28086A1 (https=)
NO (1) NO20061180L (https=)
TW (1) TW200530232A (https=)
WO (1) WO2005023806A2 (https=)
ZA (1) ZA200601978B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504243A (ja) * 2003-09-03 2007-03-01 ニューロジェン・コーポレーション 5−アリール−ピラゾロ[4,3−d]ピリミジン類、ピリジン類、ピラジン類及び関連化合物
JP2012510992A (ja) * 2008-12-06 2012-05-17 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
JP2015509515A (ja) * 2012-03-06 2015-03-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換アザ二環およびその使用

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8273750B2 (en) 2005-06-06 2012-09-25 Takeda Pharmaceutical Company Limited Organic compounds
RU2008110941A (ru) * 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
CN102775396B (zh) 2005-11-08 2014-10-08 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的杂环调控剂
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
EP1961754A4 (en) 2005-12-15 2009-11-11 Ono Pharmaceutical Co BICYCLIC HETEROCYCLIC COMPOUND
TW200812588A (en) * 2006-05-15 2008-03-16 Neurogen Corp CRF1 receptor ligands comprising heteroaryl fused bicycles
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US9006258B2 (en) 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
WO2008076446A1 (en) * 2006-12-18 2008-06-26 Coleman Peter R Accelerated opiate dependence detoxification process
JP2010513370A (ja) * 2006-12-19 2010-04-30 エフ.ホフマン−ラ ロシュ アーゲー ピラゾロ[3,4−d]ピリミジンp38MAPキナーゼインヒビター
WO2008083070A1 (en) * 2006-12-29 2008-07-10 Neurogen Corporation Crf1 receptor ligands comprising fused bicyclic heteroaryl moieties
CN104447716A (zh) 2007-05-09 2015-03-25 沃泰克斯药物股份有限公司 Cftr调节剂
ES2588238T3 (es) * 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
MX365732B (es) 2007-12-07 2019-06-12 Vertex Pharma Procesos para producir acidos cicloalquilcarboxamido-piridin benzoicos.
EP3683218B1 (en) 2007-12-07 2024-09-18 Vertex Pharmaceuticals Incorporated Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
NZ720282A (en) 2008-02-28 2017-12-22 Vertex Pharma Heteroaryl derivatives as cftr modulators
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
AU2009322904A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
JP5989993B2 (ja) 2008-12-06 2016-09-07 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 有機化合物
KR20110098732A (ko) 2008-12-06 2011-09-01 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2010065147A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
CN102231953A (zh) 2008-12-06 2011-11-02 细胞内治疗公司 有机化合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
US8551996B2 (en) * 2009-02-20 2013-10-08 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
WO2011092290A1 (en) 2010-02-01 2011-08-04 Novartis Ag Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
UY33227A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
JP2013523833A (ja) 2010-04-07 2013-06-17 バーテックス ファーマシューティカルズ インコーポレイテッド 3−(6−(1−(2,2−ジフルオロベンゾ[d][1,3]ジオキソール−5−イル)シクロプロパンカルボキサミド)−3−メチルピリジン−2−イル)安息香酸の医薬組成物およびその投与
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP2015525202A (ja) 2012-05-03 2015-09-03 ノバルティス アーゲー グレリン受容体アゴニストとしての2,7−ジアザ−スピロ[4,5]デカ−7−イル誘導体のl−リンゴ酸塩およびその結晶形態
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
CA2906640C (en) 2013-03-15 2021-07-20 Intra-Cellular Therapies, Inc. Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors
KR102529049B1 (ko) 2013-08-14 2023-05-08 노파르티스 아게 암의 치료를 위한 조합 요법
AU2014349010C1 (en) 2013-11-12 2020-08-06 Vertex Pharmaceuticals Incorporated Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
EP2940022B1 (en) * 2014-04-30 2020-09-02 Masarykova Univerzita Furopyridines as inhibitors of protein kinases
WO2015196186A1 (en) 2014-06-20 2015-12-23 Intra-Cellular Therapies, Inc. Organic compounds
WO2016022893A1 (en) 2014-08-07 2016-02-11 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
BR112017005533B1 (pt) 2014-09-17 2023-10-10 Intra-Cellular Therapies, Inc Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
TW201625635A (zh) 2014-11-21 2016-07-16 默沙東藥廠 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3510029B1 (en) * 2016-09-07 2025-11-05 The Regents of The University of California Allosteric corticotropin-releasing factor receptor 1 (crfr1) antagonists that decrease p-tau and improve cognition
WO2018049417A1 (en) 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Novel uses
JP2020528904A (ja) 2017-07-24 2020-10-01 ヴァイティー ファーマシューティカルズ,エルエルシー RORγの阻害剤
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
CN110437846B (zh) * 2019-08-30 2022-02-25 陕西师范大学 含炔键的氟取代苯并噁唑液晶化合物及其制备方法
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502723A (ja) * 1996-08-28 2000-03-07 ファイザー・インク 置換された6,5―ヘテロ―二環式誘導体
WO2002000623A2 (en) * 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2153494C2 (ru) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция
US6020492A (en) * 1995-05-12 2000-02-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
JP2002510687A (ja) * 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ[2,3−b]ピリジンおよびピロロ[2,3−d]ピリミジン誘導体:crf1レセプタのモジュレータ
DE10229777A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
EP1620095A4 (en) * 2003-04-24 2009-04-01 Merck & Co Inc HEMMER OF ACT ACTIVITY

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502723A (ja) * 1996-08-28 2000-03-07 ファイザー・インク 置換された6,5―ヘテロ―二環式誘導体
WO2002000623A2 (en) * 2000-06-26 2002-01-03 Neurogen Corporation Aryl fused substituted 4-oxy-pyridines

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007504243A (ja) * 2003-09-03 2007-03-01 ニューロジェン・コーポレーション 5−アリール−ピラゾロ[4,3−d]ピリミジン類、ピリジン類、ピラジン類及び関連化合物
JP5147401B2 (ja) * 2005-09-06 2013-02-20 塩野義製薬株式会社 Pgd2受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
JP2012510992A (ja) * 2008-12-06 2012-05-17 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP2015509515A (ja) * 2012-03-06 2015-03-30 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 置換アザ二環およびその使用

Also Published As

Publication number Publication date
KR20060088534A (ko) 2006-08-04
AP2006003559A0 (en) 2006-04-30
AR045582A1 (es) 2005-11-02
CR8274A (es) 2008-06-10
EP1680424A2 (en) 2006-07-19
TW200530232A (en) 2005-09-16
ZA200601978B (en) 2007-05-30
MA28086A1 (fr) 2006-08-01
AU2004270713A1 (en) 2005-03-17
WO2005023806A3 (en) 2005-06-02
CA2537829A1 (en) 2005-03-17
US20060199823A1 (en) 2006-09-07
NO20061180L (no) 2006-03-31
US20050113379A1 (en) 2005-05-26
ECSP066408A (es) 2006-09-18
WO2005023806A2 (en) 2005-03-17
BRPI0414087A (pt) 2006-10-31
IL174084A0 (en) 2008-02-09
EA200600372A1 (ru) 2006-08-25
CN1878773A (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
JP2007504271A (ja) Crf1受容体リガンドである、ヘテロアリール縮合ピリジン類、ピラジン類及びピリミジン類
JP2007504243A (ja) 5−アリール−ピラゾロ[4,3−d]ピリミジン類、ピリジン類、ピラジン類及び関連化合物
TWI853802B (zh) 作為a2a/a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
US9458155B2 (en) Pyrido[4,3-b]indoles containing rigid moieties
DE60117568T2 (de) Kondensierte pyrazol derivate als protein kinase inhibitoren
US6936617B2 (en) Heteroaryl substituted fused bicyclic heteroaryl compound as GABAA receptor ligands
JP2002507996A (ja) 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
ES2551582T3 (es) Derivados de etinilo
TW201200515A (en) Heteroaromatic phenylimidazole derivatives as PDE10A enzyme inhibitors
KR20200121823A (ko) 약학적 6,5 헤테로비시클릭 고리 유도체
US7557103B2 (en) Imidazopyridazine compounds
KR20170005860A (ko) 포스포디에스테라아제 10a 억제제로서 융합된 트리아졸 유도체
JP3239506B2 (ja) 複素環式誘導体
AU2004261591A1 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazepine receptor ligands
MXPA06002556A (en) Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands
EP3597642A1 (en) Pharmaceutical 6,5 heterobicyclic ring derivatives
CN100457756C (zh) 咪唑-嘧啶类及三唑-嘧啶类:苯并二氮平受体配体
AU2023320660A1 (en) TGF-β INHIBITOR COMPOUND AND USE THEREOF
AU2013203621A1 (en) Pyrido(4,3-b)indoles containing rigid moieties
CN116669769A (zh) Helios的哌啶基小分子降解剂和使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071010

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20100901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110308